Autonomix Medical, Inc.

Autonomix Medical, Inc. is a medical device company dedicated to developing precision nerve-targeted therapies aimed at transforming the treatment of peripheral nervous system diseases. The company's mission is to significantly enhance patient outcomes by providing physicians with innovative tools that enable unparalleled precision in diagnosis and treatment. Headquartered in The Woodlands, TX, Autonomix Medical focuses on empowering future nerve-targeted treatments.

The company's core technology is a first-in-class platform system that incorporates a proprietary, catheter-based microchip sensing array. This technology is designed to detect and differentiate neural signals with high sensitivity, reportedly up to 3,000 times greater than existing technologies, and can process signals directly at the point of detection. This capability facilitates transvascular diagnosis and treatment of peripheral nervous system diseases. Autonomix Medical's approach involves a "sense, treat, and verify" methodology, utilizing radiofrequency (RF) ablation technology to precisely target and ablate specific nerves. While initially focusing on pain management associated with pancreatic cancer, the platform is designed for broad applicability across various medical fields, including cardiology, hypertension, chronic pain management, renal denervation, and other visceral and tumor-related pain conditions.

Recent developments for Autonomix Medical include the acceptance of long-term clinical data for presentation at Digestive Disease Week 2026, showcasing its transvascular radiofrequency ablation approach for pain mitigation in pancreatic adenocarcinoma. The company also presented similar data at ECIO 2026 and SIR 2026, and was selected for the Best Innovation Competition at CRT 2026. Under the leadership of President and CEO Brad Hauser, Autonomix Medical has finalized the design of its ASIC microchip for human use and is progressing towards submitting an Investigational Device Exemption (IDE) to the FDA for a pivotal clinical trial in 2025, aiming for approval in pancreatic cancer pain treatment.

Latest updates

Autonomix Data on Pancreatic Cancer Pain Relief to be Presented at Digestive Disease Week

Event summary

  • Autonomix Medical's data on a transvascular radiofrequency ablation approach for pancreatic cancer pain mitigation has been accepted for presentation at Digestive Disease Week 2026 (DDW 2026).
  • The presentation, titled “Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation,” will occur May 2–5, 2026, in Chicago, IL and virtually.
  • Dr. Robert Schwartz, Co-Founder and Chief Medical Officer, emphasized the importance of data validation at prominent conferences.
  • The technology is still investigational and has not been cleared for marketing in the United States.

The big picture

Autonomix is targeting a significant unmet need in pancreatic cancer pain management, a market with limited effective solutions. The company's platform technology has potential beyond pain management, but its success hinges on demonstrating clinical efficacy and navigating the regulatory hurdles associated with novel medical devices. The acceptance at DDW signals a step towards validation, but long-term clinical outcomes and market adoption remain critical.

What we're watching

Clinical Adoption
The reception of the data at DDW 2026 will be a key indicator of potential adoption by gastroenterologists and surgeons, influencing the timeline for broader clinical use.
Regulatory Pathway
The long-term data presented may inform Autonomix's strategy for FDA approval, and the complexity of the technology could lead to a protracted regulatory review process.
Competitive Landscape
How Autonomix’s approach compares to existing pain management solutions, particularly in the context of pancreatic cancer, will determine its market penetration and pricing power.
CID: 2455